Related Experiment Video
Updated: Sep 15, 2025

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
Vessel Patency After Femoropopliteal Drug-Coated Balloon Therapy in Patients on Hemodialysis
Yasutaka Yamauchi1, Mitsuyoshi Takahara2, Yoshimitsu Soga3
1Cardiovascular Center, Takatsu General Hospital, Kawasaki, Japan.
Insights
Drug-coated balloons (DCBs) offer a reasonable treatment for femoropopliteal lesions in hemodialysis (HD) patients. Restenosis risk factors in HD patients include poor runoff, prior therapy, lesion location, calcification, and specific balloon types.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Nephrology
Background:
- Drug-coated balloons (DCBs) are a standard treatment for femoropopliteal lesions.
- Large-scale prospective data on DCB use in hemodialysis (HD) patients is limited.
Purpose of the Study:
- To assess restenosis risk after DCB therapy in patients undergoing hemodialysis.
- To identify factors associated with restenosis in this patient population.
Main Methods:
- Analysis of a multicenter prospective study database (March 2018-December 2019).
- Inclusion of 991 lesions from patients on HD out of 3,165 total lesions.
- Primary outcome: freedom from restenosis; propensity-score matching used for comparison.
Main Results:
- Hemodialysis patients were younger but had higher rates of diabetes and chronic limb-threatening ischemia.
- One-year freedom from restenosis was 82.2% in HD vs. 85.8% in non-HD; three-year rates were 61.9% vs. 66.3%.
- Independent restenosis predictors in HD patients included no below-the-knee runoff, prior endovascular therapy, popliteal lesion, severe calcification, Lutonix use, and severe dissection.
Conclusions:
- Drug-coated balloon angioplasty is a viable endovascular treatment option for femoropopliteal lesions in patients requiring hemodialysis.
- Understanding specific risk factors is crucial for optimizing outcomes in this high-risk group.
Background:
Drug-coated balloons (DCBs) are widely used as a core treatment for femoropopliteal lesions, but no largescale prospective studies have evaluated DCB in hemodialysis (HD) patients.
Objectives:
The authors sought to clarify restenosis risk and associated factors after DCB therapy for symptomatic femoropopliteal artery disease in patients on HD.
Methods:
We analyzed the database of a multicenter prospective study that registered patients undergoing DCB treatment (either Lutonix or IN.PACT Admiral) from March 2018 to December 2019. Of the 3,165 registered lesions, 991 lesions were in patients on HD. The primary outcome was freedom from restenosis.
Results:
The HD group was younger (72 ± 9 years vs 76 ± 9 years) and had a higher frequency of diabetes (76.5% [557/728 patients]) vs 60.8% [1,081/1,779 patients]). The prevalence of chronic limb-threatening ischemia was 52.2% (444/850 patients) vs 22.1% (437/1,977 patients). Lutonix was used in 30.6% (688/991 lesions) vs 21.3% (462/2,174 lesions), and IN.PACT Admiral was used in 69.4% (303/991 lesions) vs 78.7% (1,712/2,174 lesions). After propensity-score matching, the 1- and 3-year rates of freedom from restenosis in the HD and non-HD groups were 82.2% (95% CI: 79.0%-85.3%) vs 85.8% (83.0%-88.7%) at 1 year and 61.9% (57.7%-66.1%) vs 66.3% (62.2%-70.4%) at 3 years, respectively. In the HD group, restenosis occurred in 363 lesions during a median follow-up of 16.2 months (Q1-Q3: 7.2-35.5 months). Factors independently associated with restenosis risk in the HD group were no below-the-knee runoff, history of endovascular therapy, popliteal lesion, severe calcification, use of Lutonix, and severe dissection.
Conclusions:
DCB endovascular therapy is a reasonable treatment for femoropopliteal lesions in patients on HD.
More Related Videos
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
08:05Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
Related Concept Videos
Peripheral Artery Disease V: Postoperative Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Hemodialysis I: Introduction
Venous Thrombosis III: Interprofessional Care
Hemodialysis II: Procedure and Complications
Cardiac Catheterization IV: Nursing Management